• Fluorescein TSA Kit for Astrocyte Mapping

  2026-09-08

  Discover how the Fluorescein TSA Fluorescence System Kit can translate astrocyte atlas findings into sensitive spatial validation. This article connects regional and developmental heterogeneity with assay design, controls, and interpretation for IHC, ICC, and ISH.

• Bromodomain Inhibitor, (+)-JQ1: Applied Workflows

  2026-09-07

  Learn how to deploy (+)-JQ1 in adipogenesis, apoptosis, inflammation, and BRDT-focused research workflows. The guide combines mechanistic interpretation with practical dosing, controls, storage guidance, and troubleshooting for reproducible BET inhibition.

• Novobiocin in Reliable Viability Assays

  2026-09-07

  Learn how Novobiocin (SKU BA1116) can be integrated into antimicrobial, antiparasitic, antiviral, and cell-based viability workflows without confusing pathogen suppression with host-cell toxicity. This scenario-driven guide covers concentration selection, solvent controls, assay compatibility, interpretation, storage, and practical vendor evaluation.

• SU5416: A Metabolic Lens on Angiogenesis

  2026-09-05

  SU5416 (Semaxanib) is more than a VEGFR2 inhibitor: it can serve as a mechanistic probe for separating receptor-driven angiogenesis from metabolically activated HIF1α signaling. This article translates recent vascular-metabolism findings into sharper assay design and interpretation.

• IDH1-R132H Autopalmitoylation in Cancer Metabolism

  2026-09-04

  The reference study identifies C269 autopalmitoylation as a mutation-conferred regulatory modification that strengthens IDH1-R132H substrate and cofactor binding, dimerization, and production of the oncometabolite 2-HG. By connecting fatty-acid availability to mutant IDH1 activity, the work defines a mechanistically testable and potentially druggable vulnerability in IDH1-mutant cancers.

• KX2-391 Dihydrochloride: Assay Logic

  2026-09-04

  KX2-391 dihydrochloride is a mechanistically rich probe for Src signaling, tubulin dynamics, HBV transcription, and BoNT/A activity. This evidence-led guide shows how to choose endpoints, interpret concentration ranges, and avoid conflating biochemical potency with cellular or translational effects.

• miR-24-3p/Sp1/PI3K in Doxorubicin HF

  2026-09-03

  This study identifies miR-24-3p as a direct suppressor of Sp1 and links its activity to PI3K signaling in doxorubicin-induced heart failure. By combining rat and cardiomyocyte models with gain- and loss-of-function experiments, the work suggests that miR-24-3p silencing can reduce apoptosis and oxidative stress, although clinical translation remains unestablished.

• LY2603618: Chk1 Inhibitor Workflow Guide

  2026-09-03

  LY2603618 provides a focused way to interrogate Chk1-dependent checkpoint control, DNA damage accumulation, and chemotherapy sensitization in cancer models. This guide translates its reported cell-based conditions into practical workflows while clarifying how the compound can—and cannot—be used to study the nuclear cGAS–TRIM41 pathway described in recent genome-integrity research.

• Pazopanib Hydrochloride: Assay-Ready Insight

  2026-09-02

  Pazopanib Hydrochloride is a multi-target kinase inhibitor whose apparent activity can reflect both growth arrest and cell killing. This article translates Schwartz’s assay research into a practical framework for interpreting GW786034 responses in cancer research and anti-angiogenic studies.

• Capsazepine Workflows for TRPV1 Pain Research

  2026-09-02

  Use Capsazepine as a receptor-level pharmacology tool to separate TRPV1-dependent nociception from broader inflammatory and affective pain mechanisms. This workflow combines calcium imaging, sensory assays, TRPM8 counter-screening, and apoptosis studies while emphasizing solvent control and off-target troubleshooting.

• Gamithromycin: PK/PD Workflows for Respiratory Research

  2026-09-01

  Gamithromycin enables respiratory-pathogen studies that compare artificial medium with physiologically relevant serum and connect in vitro activity to lung exposure. This guide translates serum-potentiated MIC testing, time-kill analysis, and post-antibiotic-effect measurements into practical workflows for veterinary antimicrobial research.

• Quizartinib (AC220) Workflows for FLT3 Research

  2026-09-01

  Quizartinib (AC220) enables high-sensitivity interrogation of FLT3-driven signaling, from phosphorylation assays and AML cell viability studies to resistance-aware xenograft planning. This workflow-focused guide also shows how lessons from a mechanistically distinct virology study can improve assay controls without overstating cross-domain evidence.

• AO/PI Staining Solution for Kidney Cell Assays

  2026-08-31

  Build a more defensible viability workflow for podocytes, primary renal cells, and other difficult samples with dual-color membrane-integrity readouts. AO/PI Staining Solution supports fluorescence-based cell counting while helping separate viable cells from membrane-compromised cells, debris, and red blood cell interference.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-08-31

  The reference study identifies CD44-mediated metabolic rewiring as an essential dependency of IDH-mutant leukemia. By redirecting glucose metabolism toward NADPH production, CD44 sustains R-2HG synthesis, creating a rationale for combining mutant IDH inhibition with CD44 blockade.

• HDAC Inhibitors Repress NUT Carcinoma Programs

  2026-08-30

  Shiota and colleagues developed a dCas9-based high-throughput reporter screen to identify compounds that suppress NUT-driven transcription. The study revealed that structurally distinct HDAC inhibitors repress oncogenic megadomain activity, promote differentiation, and enhance bromodomain-inhibitor responses in preclinical NUT carcinoma models.

8003 records 1/534 page Next 12345 下5页 Last page